Original paper

PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES

Volume: 21, Pages: S281 - S282
Published: Oct 1, 2018
Abstract
The objective of this research is to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary and Slovakia separately, and to compare the results of the analyses. A deterministic 8-health state Markov cohort model was built, to support the cost-utility analyses that were performed from a third-party payer perspective in both...
Paper Details
Title
PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES
Published Date
Oct 1, 2018
Volume
21
Pages
S281 - S282
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.